Press coverage about Aegerion Pharmaceuticals (NASDAQ:AEGR) has been trending somewhat negative on Thursday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aegerion Pharmaceuticals earned a news impact score of -0.02 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 44.6259032875899 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Aegerion Pharmaceuticals (AEGR) traded up $0.10 on Thursday, reaching $1.97. 2,168,900 shares of the company’s stock were exchanged, compared to its average volume of 635,262. The stock has a market capitalization of $56.69, a PE ratio of -0.33 and a beta of 0.50. The company has a current ratio of 1.02, a quick ratio of 0.67 and a debt-to-equity ratio of -19.22. Aegerion Pharmaceuticals has a twelve month low of $1.23 and a twelve month high of $10.85.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3125665/somewhat-critical-press-coverage-somewhat-unlikely-to-impact-aegerion-pharmaceuticals-aegr-share-price.html.
Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.
Receive News & Ratings for Aegerion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.